A Randomised, Controlled, Open-label Phase III Clinical Trial in Patients With Primary or Recurrent Clostridioides Difficile (CD) Infection, to Evaluate the Efficacy and Safety of Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin.
Latest Information Update: 03 Nov 2025
At a glance
- Drugs MBK 01 (Primary) ; Fidaxomicin
- Indications Clostridium difficile infections
- Focus Registrational; Therapeutic Use
- Sponsors Mikrobiomik
Most Recent Events
- 03 Nov 2025 New trial record